Nine patients (6 females and 3 males) with primary hyperlipemia (6 with type Ila, I with type Ilb, and 2 with type V) were treated with gemfibrozil (CI-719) on an outpatient basis in a controlled clinical trial. The ages of the patients ranged from 52 to 72 years. Mean weight in percentage terms calculated from the Broca index was 102.6±17.3. All patients were instructed to maintain their normal eating habits during the study. None of them had undergone previous antihyperlipidmmic drug treatment. Patients with secondary hyperlipoproteinamia, chronic liver or kidney diseases, or disturbances of the haematopoietic system were not included. No concurrent medication with agents known to have an effect on serum lipids was given.
Procedure
Placebo phase: All patients received four placebo capsules daily for a period of eight weeks. During this phase, serum cholesterol and serum triglycerides were determined a total of three times (each test after 14 hours of fasting) using enzymatic methods. The type of hyperlipidwmia was determined by means of lipid electrophoresis on agarose gel. Clinical examinations in which body weight, blood pressure, and vascular status were ascertained were carried out at each control session during both the placebo and test phases, as were determinations of the following parameters: blood sedimentation rate, blood count, mg/ml 300-Cholesterol the 800 mg, 1200 mg or 1600 mg level), this dosage was then maintained for at least an additional 12 weeks.
The three pre-therapy tests of serum lipids and other parameters took place during the placebo phase at two to three week intervals. In the therapy phase, tests were carried out at two week intervals until the final dosage level was ascertained, and thereafter at four week intervals over a period of 12 weeks.
Results
The cholesterol and triglyceride lowering effects of gemfibrozil 800-1200 mg/day in 3 type II patients are shown in Figs 1, 2 and 3. The goal of a 20% decrease in the serum cholesterol level as compared with the pretreatment mean was reached in all 3 patients. The triglyceride values of the 2 type Ila patients remained at normal levels (Figs 1 and 2). In the type lib patient, a clear decrease from elevated triglyceride values to normal values was achieved (Fig 3) . All three patients successfully completed the clinical trial with a dosage of 800-1200 mg per day.
The therapy was continued with increased dosage levels for the 4 additional type Ila patients. The cholesterol lowering effects are shown in Fig 4 Fig 6 shows the behaviour of the serum lipids in the 2 type V patients. Their triglyceride levels decreased during a relatively short treatment period with 800 or 1200 mg of gemfibrozil, respectively, from mean pretreatment values between 1000 and 2000 mg/100 ml to values between 250 and 500 mg.
Of the other biochemical findings, SGOT, ASP and CPK (measured in mU) have so far been analysed. For each parameter the lowest value in the pretreatment period was compared to the highest value during the therapy period.
A slight increase in SGOT (Fig 7) , within the normal range, was observed for the therapy phase in 2 cases (Patients 4 and 13). A decrease occurred in 3 patients (6, 9 and 10), and no change was observed in the 4 additional patients (1,7, 8 and 14) . ASP (Fig 8) showed an increase for the therapy phase, also within normal limits, in 5 patients (Patients 1, 8, 9, 13 and 14); a slight decrease in 3 patients (4, 6 and 7); no change in 1 patient (10).
One patient (14) showed a highly pathological increase in CPK. However, no evidence, either clinical, electrocardiographic, nor enzymatic, could be found to show an infarct. The increase may have been due to the hard physical labour which this patient performed daily during the therapy phase. Five other patients (1, 4, 6, 7 and 10) showed an increase in CPK which was not clinically relevant, and a decrease was observed in 3 patients (8, 9 and 13). figures. Professor Nikkilai's starting value of LDL cholesterol in type IV patients was 4 mmol/l rising to 6 mmol/l. In the type II patients the mean level was 7 mmnol/l, falling to 5 mmol/l. The ideal hypolipidwemic drug would be one which by definition lowered the circulating lipids, both cholesterol and triglycerides, and also the lipoprotein levels. It seemed to him unlikely that *any drug acting by one mechanism would be able to achieve this. The causes of hyperlipidwmia were extremely complex. One must distinguish the genetic (primary), the acquired (secondary), the primary cases with secondary effects, and so on. The wide and somewhat divergent experience which had been reported was not surprising.
He suggested that more attention be given to the type of patient being treated. A type II patient with chronic alcoholism and with liver damage and kidney disease who was addicted to eating large quantities of dairy products would not give the same results as a patient with a pure genetic defect.
He was also surprised that the LDL cholesterol level was so high in Professor Nikkild's type IV patients, and that the VLDL triglyceride level was relatively low, about 3 mmol/l on average. With cholesterol levels as high as this, perhaps it would be appropriate to redefine type IV and to distinguish it from type ilb.
Professor L A Carlson (Chairman) endorsed Professor Wynn's comments on the definition of hyperlipicdemia and said that all definitions were arbitrary for the common types of hyperlipidaemia. A variety of criteria were usedtotal lipids, total cholesterol, total triglycerides or criteria arrived at by measuring lipoproteins. Again, the definition of types was arbitrary depending on use of the upper 90%, 95% or 99% of the normal population in the definition of 'elevated'. A patient who is type IV one day may be type Ilb on another. In genetic types, e.g. type Ila with xanthoma, there was less need to struggle about definitions.
Professor Nikkilii replied to Dr Vessby's last question on alcohol abuse in the 2 resistant patients. One was an alcohol user with very high serum triglyceride levels. When this became apparent, alcohol determinations were made with every lipid analysis. They were all negative, which showed he was sobe'r on his visits to the clinic, but such tests gave no information on his drinking pattern between visits.
Dr A G Olsson (Stockholm) commented on Professor Nikkild's low level of hepatic lipase activity in type Ila. He asked whether similar investigations had been made in type JIb. He was also interested in the effects of gemfibrozil on the hepatic lipase in type Ila as well as the effects reported in type IIb and type IV. minutes might have shown a changing insulin concentration.
Professor Carlson asked Professor Irsigler whether the response of his type V patients to gemfibrozil was also seen with clofibrate. Unfortunately Professor Irsigler had not conducted such a study but Professor Carlson's own work suggested that clofibrate was not very effective in type V individuals.
Professor B Lewis (London) asked Professor Nikkila whether the rise in LDL cholesterol was related to the severity of the hypertriglyceridemia as had been described for other drugs. In particular, he wondered if the rise occurred chiefly in type V patients or whether it was also seen equally in the type IVs.
Professor Nikkilii said that in the limited number of patients in their study, there was no correlation with the initial level of LDL. Most patients had normal LDL levels to start with. Neither did they find any correlation between the increase in postheparin plasma lipoprotein lipase activity and the increase in LDL. This was a correlation which might be expected with a good clearance of VLDL triglyceride, giving an increase in LDL as a product, but it was not observed.
Professor Irsigler commented on the question of patient compliance. He asked if it would be possible to assay blood samples for gemfibrozil or Metabolite III. If it were possible, it might be a suitable check of adherence to the treatment regime.
Dr R A Okerholm (Ann Arbor) said the GLC assays for gemfibrozil and for Metabolite III were quite simple.
Professor Carlson said that the possibility still existed that the patient might have only taken the tablets the day before sampling.
Dr R A Riemersma (Edinburgh) had used such an assay procedure in animal investigations. An internal standard is recommended. There now exists a hexanoic analogue of CI-719 which does not interfere with free fatty acid (FFA) estimations and gives a convenient method for measuring both the drug and FFA levels or spectra.
Dr Okerholm confirmed that the method he described used a different internal standard to the earlier GLC method and it did not interfere with other determinations in plasma, urine or bile from rat, dog, monkey or man.
Professor Nikkila said that hepatic lipase activity was very low in many cases of monogenic type Ila and that it was normal or elevated in many patients with familial type IIb disease. He had no experience of the effects of gemfibrozil on hepatic lipase in type Ila patients and did not know if it was increased or not.
With regard to patient typing and the limits of LDL cholesterol, they used an upper limit of 5.5 mmol/l for LDL cholesterol, which was approximately the 90% limit of their population and also the Swedish population. It corresponded to a figure of more than 200 mg/100 ml. He agreed with the Chairman that definitions are always difficult because on one day a patient might have an LDL cholesterol of 5.7 mmol/l and thus be type IIb, but after one week without any treatment he might have a concentration of 5.3 mmol/l, putting him into the type IV category.
Dr D J Galton (London) questioned Professor
Nikkila on his speculation about the increase in lipoprotein in lipase mediating the effect of gemfibrozil on the fall in triglycerides. He wondered if the drug might interfere with the fatty acid assay wvhich Professor Nikkila was using to measure these lipases, since the drug itself is a type of fatty acid derivative.
Professor Nikkila doubted this, because they used a radioactive assay and measured only radioactive free fatty acids, a measurement with which the drug dose does not interfere. In reply to the Chairman's question, he said that the last drug dose was given more than 12 hours before the estimation, so that drug concentration in any case would be very low.
Dr P Ghosh (Cambridge) suggested that Professor Nikkila's data on the glucose and insulin curve might be altered by separating them into two groups, those with normal and those with decreased glucose tolerance. In addition, he had taken blood samples from fasting patients and at one and two hours after giving glucose. He wondered if more information would perhaps have been obtained by taking more frequent blood samples.
Professor Nikkila said that separation of the normal from the decreased glucose tolerance patients revealed no influence of the drug. Nor did he feel that an increased number of samples would have revealed a significant effect, since the data showed little variation when compared to intra-individual variations in glucose tolerance tests in general. However, he agreed with Dr Ghosh that blood samples taken at 30 or 45
